Langley Wealth Management’s GSK GSK Stock Holding History

Langley Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$234K	Buy	+4,467	New	+$236K	0.23%	108

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Langley Wealth Management's GSK Position: Q2 2026 in Review

Langley Wealth Management opened a new position in GSK (GSK) in Q2 2026: 4,467 shares worth $234K. The stake represents 0.23% of the portfolio and ranks #108 among its holdings.

999 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Langley Wealth Management held 4,467 shares of GSK worth $234K as of Q2 2026.
GSK was a new Langley Wealth Management position in Q2 2026.
GSK made up 0.23% of Langley Wealth Management's portfolio in Q2 2026, its #108 holding.
999 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Langley Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.